Ayala Pharmaceuticals to Present at 2019 Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)-- Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 10:30am ET in New York, NY.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For more information, visit www.ayalapharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190916005012/en/

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Ayala Pharmaceuticals:
+1-857-444-0553
[email protected]

Source: Ayala Pharmaceuticals, Inc.

You May Also Be Interested In

• Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize
• Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
• Sean Kirtz and Lady Hammers Earn 3rd Place at Midwest Nationals